The role of inflammation in atherothrombosis: Current and future strategies of medical treatment

Medical Science Monitor

Volumn 10, Issue 12, 2004, Pages

  Geisler, Tobias ^a   Bhatt, Deepak L ^b  

^a Klinikum Schwalmstadt   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiplatelet therapy; Atherosclerosis; Inflammation; Statins

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; AUTACOID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARVEDILOL; CD40 LIGAND; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROPRANOLOL; PROSTAGLANDIN SYNTHASE INHIBITOR; RAMIPRIL; ROFECOXIB; TIROFIBAN; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SCREENING; DRUG UTILIZATION; DYSLIPIDEMIA; HEART INFARCTION; HEART PROTECTION; HUMAN; INFLAMMATION; NONHUMAN; OUTCOMES RESEARCH; PREDICTION; REVIEW; RISK ASSESSMENT; THROMBOCYTE AGGREGATION INHIBITION; TISSUE STRUCTURE;

EID: 13944263244     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med, 1999; 340: 115-26
2. Rong JX, Rangaswamy S, Shen L et al: Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation. Arterioscler Thromb Vasc Biol, 1998; 18: 1885-94
3. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med, 1994; 330: 1431-38
4. Davies MJ, Gordon JL, Gearing AJ et al: The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis J Pathol, 1993; 171: 223-29
5. Wang J, Sica A, Peri G et al: Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arteriosclerosis, 1991; 11: 1166-74
6. Bendeck MP, Irvin C, Reidy MA: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res, 1996; 78: 38-43
7. Clarkson TB, Prichard RW, Morgan TM et al: Remodeling of coronary arteries in human and nonhuman primates. JAMA, 1994; 271: 289-94
8. Glagov S, Weisenberg E, Zarins C et al: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med, 1987; 316: 371-75
9. Kiechl S, Egger G, Mayr M et al: Chronic Infections and the Risk of Carotid Atherosclerosis. Circulation, 2001; 103: 1064
10. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link? Lancet, 1997; 350: 430-36
11. Minick CR, Fabricant CG, Fabricant J, Litrenta MM: Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Path, 1979; 96: 673-706
12. Saikku P, Leinonen M, Mattila K et al: Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet, 1988; 2: 983-86
13. Grattan MT, Moreno-Cabral CE, Starnes VA et al: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA, 1989; 261: 3561-66
14. Danesh J, Whincup P, Walker M et al: Chlamydia pneumoniae IgG titers and coronary heart disease: prospective study and meta-analysis. BMJ, 2000; 321: 208-13
15. Biasucci LM, Liuzzo G, Ciervo A et al: Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation, 2003; 107(24): 3015-17
16. Zhou YF, Yu ZX, Wanishsawad C et al: The immediate early gene products of human cytomegalievirus increase vascular smooth muscle cell migration, proliferation and expression of PDGF β-receptor. Biochem Biophys Res Commun, 1999; 256: 608-13
17. Shishehbor MH, Bhatt DL, Topol EJ: Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med, 2003; 70(7): 634-40
18. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 2003; 107(3): 363-69
19. Nieminem MS, Mattila K, Valtonen V: Infection and inflammation as risk factors for myocardial infarction. Eur Heart J, 1993; 14(Suppl.K): 12-16
20. Ridker PM, Cushman M, Stampfer MJ et al: Inflammation, Aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997; 14: 973-79
21. Harris TB, Ferrucci L, Tracy RP et al: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med, 1999; 106(5): 506-12
22. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol, 1996; 144(6): 537-47
23. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001; 285: 2481-85
24. Chew DP, Bhatt DL, Robbins MA et al: Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation, 2001; 104(9): 992-97
25. Lenderink T, Boersma E, Heeschen C et al: Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J, 2003; 24: 77-85
26. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000; 102(18): 2165-68
27. Cermak J, Key NS, Bach RR et al: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood, 1993; 82: 513-20
28. Bhatt DL, Topol EJ: Need to test the arterial inflammation hypothesis. Circulation, 2002; 106(1): 136-40
29. Bhatt DL, Topol EJ: The arterial inflammation hypothesis. Arch Intern Med, 2002; 162(19): 2249-50
30. Tomoda H, Aoki N: Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J, 2000; 140(2): 324-28
31. Ridker PM, Rifai N, Pfeffer MA et al: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1999; 100(3): 230-35
32. Seino Y, Ikeda U, Ikeda M et al: Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine, 1994; 6: 87-91
33. Yamashita H, Shimada K, Seki E et al: Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol, 2003; 91(2): 133-36
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 2000; 101(15): 1767-72
35. Miyao Y, Yasue H, Ogawa H et al: Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J, 1993; 126(6): 1299-304
36. Biasucci LM, Liuzzo G, Fantuzzi G et al: Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation, 1999; 99: 2079-84
37. Blankenberg S, Tiret L, Bickel C et al: Interleukin-18 is a strong predictor of cardiovascular death, stable and unstable angina. Circulation, 2002; 106(1): 24-30
38. Anguera I, Miranda-Guardiola F, Bosch X et al: Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J, 2002; 144(5): 811-17
39. Old LJ: Tumor necrosis factor (TNF). Science, 1985; 230: 630-33
40. Kern PA, Saghizadch M, Ong JM et al: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest, 1995; 95: 2111-19
41. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science, 1993; 259: 87-91
42. Hotamisligil GS, Arner P, Caro JF et al: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest, 1995; 95: 2409-15
43. Skoog T, Dichtl W, Boquist S et al: Plasma tumor necrosis-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J, 2002; 23(5): 345-47
44. Cusack MR, Marber MS, Lambiase PD et al: Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol, 2002; 39(12): 1917-23
45. Cicala C, Cirino G: Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk Life Sci, 1998; 62: 1817-24
46. Danesh J, Collins R, Appleby P et al: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA, 1998; 279: 1477-82
47. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med, 1984; 311: 501-5
48. Meade TW, Mellows S, Bronzovic M et al: Hemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, 1986; 2: 533-37
49. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA, 1987; 258: 1183-86
50. Yarnell JW, Baker IA, Sweetnam PM et al: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: The Caerphilly and Speedwell collaborative heart disease studies. Circulation, 1991; 83: 836-44
51. Montalescot G, Ankri A, Vicaut E et al: Fibrinogen After Coronary Angioplasty as a Risk Factor for Restenosis. Circulation, 1995; 92: 31-38
52. Hirano K, Miki M, Yasuda H et al: Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radical Research, 1994; 21: 267-76
53. Clarke R, Daly L, Robinson K et al: Hyperhomocysteinemia: an independent risk factor for vascular disease. New Engl J Med, 1991; 324: 1149-55
54. Nygard O, Nordrehaug JE, Refsum H et al: Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease. N Engl J Med, 1997; 337: 230-36
55. Selhub J, Jacques PF, Wilson PW et al: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA, 1993; 270: 2693-98
56. Ubbink JB: Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr Rev, 1994; 52: 383-93
57. 6 from Diet and Supplements in Relation to Risk of Coronary Heart Disease among Women. JAMA, 1998; 279: 359-64
58. 12 in reduction of risk of vascular disease. Lancet, 2002; 359: 227-28
59. 6 on Clinical Outcome After Percutaneous Coronary Intervention. The Swiss Heart Study: A Randomized Controlled Trial. JAMA, 2002; 288: 973-79
60. 2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb, 1994; 14: 746-52
61. Qian H, Neplioueva V, Shetty GA et al: Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation, 1999; 99: 2979-82
62. Wever RMF, Lūscher TF, Cosentino R, Rabelink TJ: Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation, 1998; 97: 108
63. Beckman JS, Beckman TW, Chen J et al: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA, 1990; 87: 1620
64. Wilcox JN, Subramanian RR, Sundell CL et al: Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol, 1997; 17: 2479-88
65. Detmers PA, Hernandez M, Mudgett J et al: Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol, 2000; 165(6): 3430-35
66. Shears LL, Kibbe MR, Murdock AD et al: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg, 1998; 187: 295-306
67. Kibbe MR, Li J, Nie S et al: Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg, 2000; 31: 1214-28
68. Henn V, Slupsky JS, Gräfe M et al: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998; 351: 591-94
69. Schönbeck U, Mach F, Sukhova GK et al: Regulation of matrix metalloproteinases expression in human vascular smooth muscle cells by T-lymphocytes: a role for CD40 signalling in plaque rupture? Circ Res, 1997; 81(3): 448-54
70. Bavendiek U, Libby P, Kilbride M et al: Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem, 2002; 277(28): 25032-39
71. Schonbeck U, Mach F, Sukhova GK et al: CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol, 2000; 156(1): 7-14
72. Lindmark E, Tenno T, Siegbahn A: Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol, 2000; 20(10): 2322-28
73. Heeschen C, Dimmeler S, Hamm CW et al: CAPTURE Study Investigators. Soluble CD40 Ligand in Acute Coronary Syndromes. N Engl J Med, 2003; 348(12): 1104-11
74. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994; 94: 2493-503
75. Galis ZS, Muszynski M, Sukhova GK et al: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res, 1994; 75: 181-89
76. Saren P, Welgus HG, Kovanen PT: TNF-α and IL-1β selectively induce expression of 92kDa gelatinase by human macrophages. J Immunol, 1996; 157: 4159-65
77. Uzui H, Harpf A, Liu M et al: Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation, 2002; 106(24): 3024-30
78. Li Z, Li L, Zielke HR et al: Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol, 1996; 148: 121-28
79. Schoenhagen P, Vince DG, Ziada KM et al: Relation of matrix- metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol, 2002; 89(12): 1354-59
80. Zempo N, Kenagy RD, Au YPT et al: Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg, 1994; 20: 209-17
81. Blankenberg S, Rupprecht HJ, Poirier O et al. and for the AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003; 107(12): 1579-85
82. Wei S, Chen Y, Chung L et al: Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. J Biol Chem, 2003; 278(11): 9831-34
83. Lorenzet R, Napoleone E, Celi A et al: Cell-cell interaction and tissue factor expression. Blood Coagul Fibrinolysis, 1998; 9(Suppl.1): S49-59
84. Crossman DC, Carr DP, Tuddenham EGD et al: The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem, 1990; 265: 9782-87
85. Conway EM, Bach R, Rosenberg RD, Konigsberg WH: Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res, 1989; 53: 231-41
86. Suefuji H, Ogawa H, Yasue H et al: Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J, 1997; 134: 253-59
87. Presta L, Sims P, Meng YG et al: Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost, 2001; 85(3): 379-89
88. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-89
89. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339: 1349-57
90. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22
91. Schwartz GG, Olsson AG, Ezekowitz MD et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomised controlled trial. JAMA, 2001; 285: 1711-18
92. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA, 2001; 285: 430-36
93. Aronow HD, Topol EJ, Roe MT et al: Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet, 2001; 357: 1063-68
94. Chan AW, Bhatt DL, Chew DP et al: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation, 2002; 105(6): 691-96
95. Chan AW, Bhatt DL, Chew DP et al: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation, 2003; 107(13): 1750-56
96. Jukema JW, Bruschke AV, van Boven AJ et al: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation, 1995; 91: 2528-40
97. Sacks FM, Pfeffer MA, Moye LA et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-9
98. Downs JR, Clearfield M, Weis S et al: Primary prevention of acute coronary events with lovostatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary-Atherosclerosis Prevention Study. JAMA, 1998; 279: 1615-22
99. Aviram M, Rosenblat M, Bisgaier CL, Newton RS: Aton-astatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis, 1998; 138: 271-80
100. Yasanuri K, Maeda K, Minami M, Yoshikawa J: HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol, 2001; 21: 937-42
101. Fukumoto Y, Libby P, Rabkin E et al: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation, 2001; 103: 993-99
102. Corsini A, Pazzucconi F, Arnaboldi L et al: Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol, 1998; 31: 773-78
103. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 1999; 353: 983-84
104. Romano M, Mezzetti A, Marulli C et al: Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med, 2000; 48: 183-89
105. Sumi D, Hayashi T, Thakur NK et al: A HMG-CoA reductase inhibitor posseses a potent anti-atherosclerotic effect other than serum lipid lowering effects- the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis, 2001; 155: 347-57
106. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998; 97: 1129-35
107. Hoffman R, Brook GJ, Aviram M: Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis, 1992; 93: 105-13
108. Lindmark E, Siegbahn A: Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures. Effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res, 2002; 108(1): 77-84
109. Ikeda U, Shimpo M, Ohki R et al: Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension, 2000; 36: 318-25
110. Bellosta S, Via D, Canavesi M et al: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol, 1998; 18: 1671-78
111. Marz W, Winkler K, Nauck M et al: Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol, 2003; 92(3): 305-8
112. Chan AW, Bhatt DL, Chew DP et al: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation, 2003; 107(13): 1750-56
113. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA, 1975; 231: 360-81
114. Brown BG, Zhao XQ, Chalt A et al: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 2001; 345(22): 1583-92
115. Kashyap ML, McGovern ME, Berra K et al: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol, 2002; 89: 672-78
116. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet, 1997; 349: 1429-35
117. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet, 1997; 349: 1422-28
118. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable anginaor acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997; 96: 1445-53
119. The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med, 1998; 338: 1498-505
120. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet, 2001; 357: 1915-24
121. Nannizzi-Alaimo L, Alves VL, Phillips DR: Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation, 2003; 107(8): 1123-28
122. May AE, Kalsch T, Massberg S et al: Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation, 2002; 106(16): 2111-17
123. Lincoff AM, Kereiakes DJ, Mascelli MA et al: Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation, 2001; 104(2): 163-67
124. ISIS-2 Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ, 1998; 316: 1337-43
125. 4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors. J Exp Med, 1997; 185(9): 1693-704
126. Chenevard R, Hurlimann D, Bechir M et al: Selective Cox-2 inhibition improves endothelial function in coronary artery disease. Circulation, 2003; 107(3): 405-9
127. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001; 286(8): 954-59
128. CURE Study Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345: 494-502
129. Steinhubl SR, Ellis SG, Wolski K et al: Ticlopidine pre-treatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation, 2001; 103: 1403-9
130. Mehta SR, Yusuf S, Peters RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001; 358: 527-33
131. Chew DP, Bhatt DL, Robbins MA et al: Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein Am J Cardiol, 2001; 88(6): 672-74
132. Klinkhardt U, Graff J, Harder S: Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther, 2002; 71(3): 176-85
133. Gurbel PA, Malinin AI, Callahan KP et al: Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation Am J Cardiol, 2002; 90(3): 312-15
134. Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov, 2003; 2(1): 15-28
135. Marx N, Sukhova GK, Collins T et al: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999; 99: 3125-31
136. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology, 2002; 53(3): 273-77
137. Tontonoz P, Nagy L, Alvarez JGA et al: PPAR γ promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell, 1998; 93: 241
138. Ricote M, Li AC, Willson TM et al: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998; 391: 79
139. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998; 391: 82-86
140. Marx N, Froehlich J, Siam L et al: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 2003; 23(2): 283-88
141. Marx N, Imhof A, Froehlich J et al: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation, 2003; 107(15): 1954-57
142. Haffner SM, Greenberg AS, Weston WM et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002; 106(6): 679-84
143. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001; 357(9266): 1385-90
144. Orekhov AN, Andrianova IV, Rekhter MD et al: Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis, 1992; 95(1): 77-85
145. Ostlund-Lindqvist AM, Eklund A, Sjoblom L, Jonsson L: Effect of metoprolol on plasma lipids and arterial intimal lipid deposition in spontaneously hypertensive rats. Atherosclerosis, 1989; 80(2): 135-42
146. Wikstrand J: Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am Heart J, 1988; 116: 338-47
147. Donetti E, Soma MR, Barberi L et al: Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits. Atherosclerosis, 1998; 141(1): 45-51
148. Matsuda Y, Akita H, Terashima M et al: Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J, 2000; 140(5): 753-59
149. Franzen D, Seifert N, Metha A, Hopp HW: Metoprolol treatment to prevent restenosis following percutaneous transluminal coronary angioplasty. Cardiology, 2002; 97(2): 94-98
150. Jackson JD, Muhlestein JB, Bunch TJ et al: Beta-blockers reduce the incidence of clinical restenosis: Prospective study of 4840 patients undergoing percutaneous coronary revascularization. Am Heart J, 2003; 145(5): 875-81
151. Chan AW, Quinn MJ, Bhatt DL et al: Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol, 2002; 40(4): 669-75
152. Levine B, Kalman J, Mayer L et al: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med, 1990; 323(4): 236-41
153. Ohtsuka T, Hamada M, Hiasa G et al: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol, 2001; 37(2): 412-17
154. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL: Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation, 2000; 101(17): 2103-9
155. Pfeffer MA, Braunwald E, Moye LA et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 1992; 327(10): 669-77
156. Cleland JG, Erhardt L, Murray G et al: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J, 1997; 18(1): 41-51
157. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med, 2000; 342: 145-53
158. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002; 288: 2981-97
159. Williams B: Angiotensin II and the pathophysiology of cardiovascular remodelling. Am J Cardiol, 2001; 87(Suppl.): 10C-17C
160. Kranzhofer R, Bowatzki M, Schmidt J, Kubler W: Angiotensin II activates the proinflammatory transcription factor nuclear factor-kb in human monocytes. Biochem Biophys Res Commun, 1999; 257: 826-28
161. Kranzhofer R, Schmidt J, Pfeiffer CA et al: Angiotensin induces inflammatory activation of human vascular smooth muscle cells Arterioscler Thromb Vasc, 1999; 19: 1623-29
162. Warnholtz A, Nickenig G, Schulz E et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation, 1999; 99: 2027-33
163. Schindler R, Dinarello CA, Koch KM: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine, 1995; 7(6): 526-33
164. Nagata K, Ishibashi T, Sakamoto T et al: Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J Hypertens, 2001; 19(4): 775-83
165. Bauriedel G, Skowasch D, Schneider M et al: Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J, 2003; 145(2): 343-48
166. Sander D, Winbeck K, Klingelhōfer J et al: Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation, 2002; 106: 2428-33
167. Parchure N, Zouridakis EG, Kaski JC: Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of chlamydia pneumoniae infection. Circulation, 2002; 105: 1298-303
168. Kuvin JT, Gokce N, Holbrook M et al: Effect of short-term antibiotic
169. Gieffers J, Füllgraf H, Jahn J et al: Chlamydia pneumoniae infection is refractory to antibiotic treatment. Circulation, 2001; 103: 351-56
170. Bozkurt B, Torre-Amione G, Smith Warren M et al: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation, 2001; 103: 1044-47
171. Gullestad L, Aass H, Fjeld JG et al: Immunomodulating therapy with intravenous immunoglobulin in patients with chronicheart failure. Circulation, 2001; 103: 220-25
172. Nicoletti A, Kaveri S, Caligiuri G et al: Immunoglobulin Treatment Reduces Atherosclerosis in apo E Knockout Mice. J Clin Invest, 1998; 102: 910-18
173. Yuan Z, Kishimoto C, Sano H et al: Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol, 2003; 285(2): H899-906
174. Saadeddin SM, Habbab MA: Percutaneous coronary intervention in the context of systemic inflammation: more injury and worse outcome. Med Sci Monit, 2003; 9(8): RA193-RA197